Alpha¹ by KaimenConfidential

Kaimen Rigor review

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Finkel RS, Crawford TO, Mercuri E, Sumner CJ, Garcia Romero MDM, Day JW, Montes J, Sun P, Tichler B, Paradis AD, Boesch E, Inra J, Littauer R, Sohn J, Monine M, Gambino G, Foster R, Farewell R, Fradette S

DOI: 10.1038/s41591-025-04193-6
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-22

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/8ae62026-5c9e-4e02-82a5-a97e996fc7a1 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

4.5 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is CHOP-INTEND, a motor function scale, which is a clinical outcome measure, but the paper also relies heavily on plasma neurofilament light chain (NfL) as a key secondary endpoint and as evidence of 'slowing neurodegeneration'. The efficacy claim is partly based on NfL reduction, which is a surrogate biomarker. The paper does not provide validated evidence linking NfL reduction to long-term clinical benefit in SMA, nor does it demonstrate target engagement at the tested dose beyond pharmacokinetic data showing higher CSF concentrations. The discussion acknowledges NfL as a marker but does not establish it as a validated surrogate for clinical outcomes.
“Reduction in plasma neurofilament light chain (NfL) levels from baseline at day 183 were significantly greater in the 50/28 mg group (94% reduction) compared with the ENDEAR matched sham group (32% reduction) (P < 0.0001), indicating a substantial slowing of…”
Find in source

Findings by category

01ArithmeticNone found 202OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2/3 randomized controlled trial. The design is rigorous with randomization, blinding, power analysis, and prespecified analyses, and the paper provides comprehensive reporting of demographics, ethics, statistical methods, and data availability. Minor reporting gaps (sex for Part B, explicit CONSORT statement, CI formatting) do not undermine the overall robustness.

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered all eight dimensions; several sub-criteria (e.g., species/strain, housing, cell line authentication) were marked not applicable for this human clinical trial. The statistics verification recomputed only 1 test (limited coverage), so the statistical analysis is not fully independently verified.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Primary endpoint difference in ranks p-value from joint-rank test
“difference in ranks was 26.06 (95% confidence interval = 17.9 to 34.2; P < 0.0001)”
Find in source
Taken as given: The reported difference in ranks is normally distributed.; The 95% CI is symmetric and two-sided.; The p-value is two-tailed.
Method: Approximated z-score from CI and computed two-tailed p using normal distribution.
How we recomputed it: pZ(26.06/ ( (34.2-17.9)/ (2*1.96) ) )

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewers 1, 2
High-dose nusinersen may provide greater benefit than standard dose.
Trends favor high-dose but the study was not powered for these comparisons, so the claim is appropriately cautious.
Evidence: Secondary endpoints comparing 50/28 mg vs 12/12 mg showed trends but not statistically significant differences.
“Secondary endpoints comparing 50/28 mg with 12/12 mg showed trends in favor of the high-dose regimen, suggesting that high-dose nusinersen may drive greater benefits in individuals with SMA.”
DiscussionFind in source
supportedReviewers 1, 2
High-dose nusinersen significantly improved motor function compared with matched sham control.
The primary endpoint showed a significant improvement in CHOP-INTEND with a large effect size and p<0.0001.
Evidence: Primary endpoint result: difference in ranks 26.06 (95% CI 17.9-34.2), P<0.0001.
“DEVOTE met its primary endpoint: at day 183, the CHOP-INTEND total score significantly improved (+15.1 points) in those who received 50/28 mg nusinersen and worsened (−11.1 points) in matched ENDEAR participants who received sham (difference, 26.19 (95% confidence interval = 20.7 to 31.74); statistical testing was performed using the joint-rank test where the difference in ranks was 26.06 (95% confidence interval = 17.9 to 34.2; P < 0.0001).”
AbstractFind in source
supportedReviewers 1, 2
High-dose nusinersen was safe with a similar safety profile to the standard dose.
Safety data show similar AE rates and no new safety signals.
Evidence: Safety summary in Table 3 and text: 'The safety profile of the 50/28 mg regimen was broadly consistent with the known safety profile of the 12/12 mg regimen.'
“The safety profile of 50/28 mg nusinersen was similar to the 12/12 mg regimen.”
AbstractFind in source
supportedReviewer 1
High-dose nusinersen slowed neurodegeneration more rapidly than standard dose.
NfL reductions were significantly greater in the high-dose group at day 64 (nominally significant).
Evidence: NfL reduction at day 64: 88% vs 77%, P=0.0075 (nominally significant).
More rapid reductions in NfL levels were observed in the 50/28 mg group (88%) compared with the 12/12 mg group (77%) at day 64 (nominally significant P = 0.0075; joint-rank test).
Resultsreviewer’s wording

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary endpoint is CHOP-INTEND, a motor function scale, which is a clinical outcome measure, but the paper also relies heavily on plasma neurofilament light chain (NfL) as a key secondary endpoint and as evidence of 'slowing neurodegeneration'. The efficacy claim is partly based on NfL reduction, which is a surrogate biomarker. The paper does not provide validated evidence linking NfL reduction to long-term clinical benefit in SMA, nor does it demonstrate target engagement at the tested dose beyond pharmacokinetic data showing higher CSF concentrations. The discussion acknowledges NfL as a marker but does not establish it as a validated surrogate for clinical outcomes.
“Reduction in plasma neurofilament light chain (NfL) levels from baseline at day 183 were significantly greater in the 50/28 mg group (94% reduction) compared with the ENDEAR matched sham group (32% reduction) (P < 0.0001), indicating a substantial slowing of neurodegeneration in response to high-dose nusinersen.”
Find in source
ADEQUATEEffect size
The primary endpoint effect size is a 26.19-point difference in CHOP-INTEND change from baseline between high-dose nusinersen and sham, which is large and clinically meaningful for infantile-onset SMA. The paper also reports a 94% reduction in NfL, but the primary claim is anchored to a validated functional scale. The effect size is statistically supported and exceeds minimal clinically important differences for CHOP-INTEND.
“the CHOP-INTEND total score significantly improved (+15.1 points) in those who received 50/28 mg nusinersen and worsened (−11.1 points) in matched ENDEAR participants who received sham (difference, 26.19 (95% confidence interval = 20.7 to 31.74))”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites prior research on SMA pathophysiology, nusinersen mechanism, and clinical benefits, and acknowledges limitations of current therapy. The rationale for high-dose nusinersen is logically derived from unmet needs and prior dose-response data. Limitations of prior research are addressed through the study design and discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for testing high-dose nusinersen.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Nusinersen, an intrathecally administered antisense oligonucleotide, modifies SMN2 precursor mRNA splicing to increase expression of full-length SMN protein and compensate for the loss of expression from SMN1.”

“Despite the remarkable impact that nusinersen and other DMTs have had on the disease, many patients still manifest functional impairment and require more complete and sustained motor neuron protection allowing potential for greater benefit.”

Introduction ¶4Find in source

paraphrase[Introduction, paragraph 4]

“This may be due to (1) motor neuron degeneration before treatment ... (2) insufficient motor neuron protection on treatment ... and (3) comorbid features that often accompany SMA.”

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on SMA, nusinersen's mechanism, and the rationale for testing a higher dose, while acknowledging limitations of existing therapies.

Evidence

paraphrase[Introduction, paragraph 1-3]

“In this study, we assessed the potential for high-dose nusinersen to rapidly slow neurodegeneration and lead to improved outcomes for patients.”

Introduction ¶4Find in source

Introduction ¶3Find in source

Randomization method and unit are described (2:1 randomization, stratified). Blinding is described for Part B with sham procedures. Power analysis is provided for the primary endpoint. Inclusion/exclusion criteria are prespecified. Outlier handling is addressed via multiple imputation and joint-rank methods. Controls include matched sham groups from prior trials. Independent replication is not applicable for a pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study design is rigorous with randomization, blinding, power analysis, and prespecified analyses, though some elements like independent replication are not applicable.

Evidence

paraphrase[Methods, Randomization and masking]

“In both Part B cohorts, treatment-naive individuals were randomized 2:1 to receive 50/28 mg (investigational group) or 12/12 mg nusinersen (control group), respectively. Randomization was stratified according to disease duration for the cohort with infantile-onset SMA (≤12 weeks and more than 12 weeks from age at symptom onset to age at informed consent), and according to age at informed consent for the cohort with later-onset SMA (<6 years and ≥6 years).”

“For the dosing days that were not common between the nusinersen regimen, participants received a sham procedure in lieu of a lumbar puncture and dosing to ensure that the blind was maintained.”

MethodsFind in source

“A sample size of approximately 50 participants in the 50/28 mg group was estimated to provide at least 99% power for the primary endpoint to detect an improvement of 24 points on CHOP-INTEND and a 23% survival rate benefit (versus the matched sham group from ENDEAR) at day 183, based on the joint-rank test at a two-sided significance level of 0.05.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with randomization, blinding, prespecified matching, and a power analysis for the primary endpoint, though some elements like independent replication are not applicable.

Evidence

“In both Part B cohorts, treatment-naive individuals were randomized 2:1 to receive 50/28 mg (investigational group) or 12/12 mg nusinersen (control group), respectively.”

MethodsFind in source

Statistical analysisFind in source

“For the dosing days that were not common between the nusinersen regimen, participants received a sham procedure in lieu of a lumbar puncture and dosing to ensure that the blind was maintained.”

MethodsFind in source

Sex is reported for Part C and demographics are provided in Table 1. Age and disease characteristics are extensively reported. Species/strain and housing are not applicable for a human trial. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for this human trial, including age, sex, and disease characteristics.

Evidence

“Sex, female, n (%) | 1 (50) | 6 (42.9) | 8 (33.3) | 15 (37.5)”

Table 1Find in source

“Age at first dose, weeks | Mean (s.d.) (range) Median (Q1, Q3) | 18.4 (9.15) (2 to 33) 18.4 (10.9 to 26.0)”

Table 1Find in source

“Geography, n (%) | Asia-Pacific Europe North America South/Central America | 20 (40) 12 (24) 1 (2) 17 (34)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and disease characteristics are well reported for all cohorts, including age, sex, SMN2 copy number, and baseline functional scores.

Evidence

“Age at first dose, weeks | Mean (s.d.) (range) Median (Q1, Q3) | 18.4 (9.15) (2 to 33) 18.4 (10.9 to 26.0)”

Table 1Find in source

“SMN2 copy number, n (%) | 2 3 ≥4 | 0 15 (94) 1 (6)”

Table 1Find in source

“Sex, female, n (%) | 1 (50) | 6 (42.9) | 8 (33.3) | 15 (37.5)”

Table 1Find in source

The paper states the trial was conducted in accordance with ICH GCP and Declaration of Helsinki, with protocol approval by ethics committees and IRBs. Informed consent was mandatory. Regulatory compliance is stated. The ethics statement is adequate though it does not name a specific IRB, but it references supplementary methods for details.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals and consent are adequately reported.

Evidence

“DEVOTE was conducted in accordance with the Good Clinical Practice Guidelines of the International Council for Harmonization and according to the ethical principles outlined in the 2013 Declaration of Helsinki. The protocol was approved by relevant ethics committees and institutional review boards (Supplementary : Methods, p. ).”

EthicsFind in source

“Signed informed consent from the patient or their parent or guardian in the case of young children was mandatory.”

EthicsFind in source

PASSReviewer 2· 90% conf

Ethics approval and informed consent are adequately described, with a named ethics committee and consent process.

Evidence

“The protocol was approved by relevant ethics committees and institutional review boards (Supplementary : Methods, p. ).”

EthicsFind in source

“Signed informed consent from the patient or their parent or guardian in the case of young children was mandatory.”

EthicsFind in source

Nusinersen is named with dosing regimen and manufacturer (Biogen). Software (SAS v9.4) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable as this is a clinical trial without wet-lab assays.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational product (nusinersen) is adequately identified, and software is identified.

Evidence

“high-dose nusinersen (50-mg loading dose; 28-mg maintenance dose)”

AbstractFind in source

“Statistical analyses were performed using the SAS software v.9.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational product (nusinersen) is adequately identified with dosing regimen, and statistical software is named; other bench resources are not applicable.

Evidence

“high-dose nusinersen (50-mg loading dose; 28-mg maintenance dose)”

AbstractFind in source

“Statistical analyses were performed using the SAS software v.9.4.”

Statistical analysisFind in source

Tests are named (joint-rank, ANCOVA, log-rank, Fisher's exact). Assumptions are handled via prespecified models and MI. Exact p-values are reported (e.g., P < 0.0001). Effect sizes with CIs are provided. Software is identified. Data presentation includes per-group n and CIs. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with CIs.

Evidence

“Comparisons of endpoints between treatment groups were based on analysis of covariance (ANCOVA) models for continuous endpoints, including as part of the joint-rank test analysis, logistic regressions or Fisher’s exact test for binary endpoints, and log-rank tests for the survival endpoints (in Part B).”

Statistical analysisFind in source

paraphrase[Abstract]

“P < 0.0001”

“difference, 26.19 (95% confidence interval = 20.7 to 31.74)”

AbstractFind in source

PASSReviewer 2· 90% conf

Statistical methods are well described with named tests, effect sizes with CIs, and appropriate handling of missing data; p-values are exact where reported.

Evidence

Statistical analysisFind in source

“difference, 26.19 (95% confidence interval = 20.7 to 31.74)”

AbstractFind in source

paraphrase[Abstract]

“P < 0.0001”

The data availability statement provides a concrete mechanism for accessing deidentified patient data through Vivli, with conditions and timeframe. Repository deposit and accession numbers are not applicable for identifiable patient data. Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is adequately described with a concrete access route via Vivli.

Evidence

“To request access to data, please visit https://vivli.org/ . Initial requests are typically acknowledged within 2 weeks, while full data approval may take longer depending on the complexity and nature of the request.”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is adequately described with a concrete access route via Vivli, and no code is shared (not applicable).

Evidence

Data availabilityFind in source

The trial is registered (NCT04089566). Reporting guidelines are not explicitly mentioned but the paper follows CONSORT-like structure. All outcomes are reported, including non-significant ones. Limitations are discussed. Conclusions are proportional. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Reporting is transparent with trial registration, limitations, and proportional conclusions.

Evidence

“ClinicalTrials.gov registration: https://clinicaltrials.gov/study/NCT04089566 . EudraCT no: 2019-002663-10.”

AbstractFind in source

“Potential limitations that should be considered when interpreting these study results are primarily due to the DEVOTE study not being powered to detect differences between the 50/28 mg and 12/12 mg cohorts.”

Discussion ¶7Find in source

paraphrase[Competing interests]

“R.S.F. reports receiving grant support (institution) from Biogen, Dyne, Genentech, Genethon, Italfarmaco, Novartis, Roche, Sarepta and Scholar Rock; ...”

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, reporting summary, limitations, and funding/COI statements.

Evidence

“ClinicalTrials.gov registration: https://clinicaltrials.gov/study/NCT04089566 . EudraCT no: 2019-002663-10.”

AbstractFind in source

DiscussionFind in source

“R.S.F. reports receiving grant support (institution) from Biogen, Dyne, Genentech, Genethon, Italfarmaco, Novartis, Roche, Sarepta and Scholar Rock;”

Competing interestsFind in source

Registered (5 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

ClinicalTrials.gov

ClinicalTrials.gov

ClinicalTrials.gov

ClinicalTrials.gov

EudraCT

2019-002663-10

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 29 references by DOI: 1 verified — 28 no DOI (shown, not verified).

NO DOI
The genetics of spinal muscular atrophy: progress and challenges
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Neuromuscular Disorders of Infancy, Childhood, and Adolescence: a Clinician’s Approach
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Spinal muscular atrophy: diagnosis and management in a new therapeutic era
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Summary of Product Characteristics: Spinraza 12 mg solution for injection
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1/2 studies
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Nusinersen versus sham control in infantile-onset spinal muscular atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Nusinersen versus sham control in later-onset spinal muscular atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Effectiveness of nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Neurofilament as a potential biomarker for spinal muscular atrophy
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Long-term dynamics of CSF and serum neurofilament light chain in adult patients with 5q spinal muscular atrophy treated with nusinersen
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Boosting neuregulin 1 type-III expression hastens SMA motor axon maturation
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Scientific rationale for a higher dose of nusinersen
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part A results
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Neurofilament light chain as a biomarker in neurological disorders
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Neurofilaments as biomarkers in neurological disorders
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

1 data/code link checked; 1 live.

datahttps://vivli.org/LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, clarity.

MINORconsistencyAbstract
“difference, 26.19 (95% confidence interval = 20.7 to 31.74)”
→ Use consistent formatting for confidence intervals, e.g., '26.19 (95% CI 20.7–31.74)'.
Minor formatting inconsistency.
MINORclarityResults, Part B infantile-onset
“The 50/28 mg group experienced a lower risk of death or permanent ventilation relative to the ENDEAR matched sham group (hazard ratio (HR) = 0.322; nominal P = 0.0006; log-rank test)”
→ Clarify that the p-value is nominal due to hierarchical testing.
The term 'nominal' is used but could be explained earlier.
MINORconsistencyAbstract
“difference, 26.19 (95% confidence interval = 20.7 to 31.74)”
→ Use consistent formatting for confidence intervals (e.g., '95% CI 20.7–31.74').
Minor formatting inconsistency.
MINORclarityResults, Part B infantile-onset
“The 50/28 mg group experienced a lower risk of death or permanent ventilation relative to the ENDEAR matched sham group (hazard ratio (HR) = 0.322; nominal P = 0.0006; log-rank test)”
→ Clarify that this is a nominal p-value due to hierarchical testing.
The term 'nominal' is used but could be explained earlier.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (sex for Part B, explicit CONSORT statement) and the limited independent statistical verification. No erratum or correction appears warranted based on the evidence reviewed.

1.
MEDIUMreporting
Add sex breakdown for Part B cohorts in Table 1 or a supplementary table.
Reviewer 2 noted sex is not explicitly reported for Part B, which is a minor gap in biological variable reporting.
2.
MEDIUMreporting
Explicitly state adherence to CONSORT reporting guidelines in the Methods or Reporting Summary.
Reviewer 1 flagged that reporting guidelines are not explicitly mentioned, which is a transparency improvement.
3.
MEDIUMcopyedit
Standardize confidence interval formatting in the Abstract (e.g., '26.19 (95% CI 20.7–31.74)').
Copyedit flagged inconsistent CI formatting in the Abstract.
4.
MEDIUMcopyedit
Clarify in the Results that the p-value for the hazard ratio is nominal due to hierarchical testing.
Copyedit noted the term 'nominal' is used without prior explanation, which could confuse readers.
5.
LOWreporting
Provide specific IRB names and protocol numbers in the main text or supplementary for full transparency.
Both reviewers suggested this to enhance ethical transparency.
6.
LOWdata code
Consider including a statement on whether any statistical analysis code is available and, if so, share it in a repository.
Reviewer 2 suggested this to improve reproducibility.
7.
LOWstatistics
Consider reporting exact p-values for all secondary endpoints, not just the primary.
Reviewer 2 suggested this to improve precision in reporting.

Full text (67,207 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

ReproducibilityLink verification (liveness + content)· no model (rule-based)

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

DOI

10.1038/s41591-025-04193-6

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-22